Government-Owned Inventions; Availability for Licensing, 52452 [2016-18689]
Download as PDF
52452
Federal Register / Vol. 81, No. 152 / Monday, August 8, 2016 / Notices
2019, Bethesda, MD 20892, 301–443–2861,
marmillotp@mail.nih.gov.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Initial
Review Group; Neuroscience Review
Subcommittee.
Date: October 27, 2016.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Alcohol Abuse
and Alcoholism, National Institutes of
Health, Terrace Level Conference Room 508–
509, 5635 Fishers Lane, Rockville, MD 20852.
Contact Person: Beata Buzas, Ph.D.,
Scientific Review Officer, National Institute
On Alcohol Abuse and Alcoholism, National
Institutes of Health, 5635 Fishers Lane, Rm.
2081, Rockville, MD 20852, 301–443–0800,
bbuzas@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.271, Alcohol Research
Career Development Awards for Scientists
and Clinicians; 93.272, Alcohol National
Research Service Awards for Research
Training; 93.273, Alcohol Research Programs;
93.891, Alcohol Research Center Grants;
93.701, ARRA Related Biomedical Research
and Research Support Awards, National
Institutes of Health, HHS)
Dated: August 2, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–18688 Filed 8–5–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Department of Health and Human
Services.
ACTION: Notice.
AGENCY:
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing and/or co-development in the
U.S. in accordance with 35 U.S.C. 209
and 37 CFR part 404 to achieve
expeditious commercialization of
results of federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing and/or co-development.
ADDRESSES: Invention Development and
Marketing Unit, Technology Transfer
Center, National Cancer Institute, 9609
Medical Center Drive, Mail Stop 9702,
Rockville, MD 20850–9702.
FOR FURTHER INFORMATION CONTACT:
Information on licensing and co-
mstockstill on DSK3G9T082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
22:23 Aug 05, 2016
Jkt 238001
development research collaborations,
and copies of the U.S. patent
applications listed below may be
obtained by contacting: Attn. Invention
Development and Marketing Unit,
Technology Transfer Center, National
Cancer Institute, 9609 Medical Center
Drive, Mail Stop 9702, Rockville, MD,
20850–9702, Tel. 240–276–5515 or
email ncitechtransfer@mail.nih.gov. A
signed Confidential Disclosure
Agreement may be required to receive
copies of the patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Title of invention: Synthetic HumanDerived Peptides and Peptidomimetics
for Cancer Therapeutics
Keywords: Rpn13, selective
proteasome inhibitor, proteasome
ubiquitin receptors, (competition:
carfilzomib and bortezomib too toxic,
resistance developed), solid tumors,
hematological cancer, HPV associated
cancer, ovarian cancer, prostate cancer,
gastric cancer, breast cancer, or
colorectal cancer
Description of Technology: FDA
approved 26S proteasome inhibitors,
such as carfilzomib and bortezomib
(Velcade®) have proven to be effective at
treating hematologic cancers. However,
resistance to these agents as well as
their toxicity have raised concerns and
highlight the need for new 26S
proteasome inhibitors.
Investigators at the NCI’s Structural
Biophysics Laboratory have developed a
new class of proteasome inhibitors.
They are hRpn2-derived peptides
capable of specifically targeting the Pru
domain of hRpn13. Disruption of the
Rpn2/Rpn13 interaction inhibits
proteolysis by a mechanism that differs
from those of the approved proteasome
inhibitors.
Potential Commercial Applications:
• New class of proteasome inhibitors,
targeting hRpn13 of the regulatory
particle.
Value Proposition:
• Synergistic with, and more specific
than, known proteasome inhibitors.
• Alternate mechanism of action
compared to approved proteasome
inhibitors.
Development Stage: Discovery (Lead
ID).
Inventor(s): Kylie J. Walters (NCI), Fen
Liu (NCI), and Xiuxiu Lu (NCI).
Intellectual Property:
HHS Reference No. E–278–2015/0–
US–01.
US Provisional Application 62/
222,530 (HHS Reference No. E–278–
2015) filed September 23, 2015 entitled
‘‘Human RPN2 Derived Peptides Useful
For Treating Cancer’’.
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
Publications: 1. Lu X., et al., 2015
PLoS One 2015 Oct 14;10(10) PMID:
26466095.
Contact Information: Requests for
copies of the patent application or
inquiries about licensing, research
collaborations, and co-development
opportunities should be sent to John D.
Hewes, Ph.D., email: john.hewes@
nih.gov.
Dated: July 26, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology
Transfer Center, National Cancer Institute.
[FR Doc. 2016–18689 Filed 8–5–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App. 2), notice is
hereby given of the meeting of the
National Cancer Advisory Board
(NCAB).
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The open
session will be videocast and can be
accessed from the NIH Videocasting and
Podcasting Web site (https://
videocast.nih.gov).
A portion of the National Cancer
Advisory Board meeting will be closed
to the public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Advisory Board.
Open: September 7, 2016, 9:00 a.m. to
05:00 p.m.
Agenda: Programs reports and
presentations; business of the Board.
Place: National Institutes of Health,
Building 31, C-Wing, 6th Floor, Room 10,
9000 Rockville Pike, Bethesda, MD 20892.
Closed: September 7, 2016, 04:00 p.m. to
05:00 p.m.
E:\FR\FM\08AUN1.SGM
08AUN1
Agencies
[Federal Register Volume 81, Number 152 (Monday, August 8, 2016)]
[Notices]
[Page 52452]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-18689]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Department of Health and Human
Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing and/or co-development in the
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve
expeditious commercialization of results of federally-funded research
and development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing and/or co-development.
ADDRESSES: Invention Development and Marketing Unit, Technology
Transfer Center, National Cancer Institute, 9609 Medical Center Drive,
Mail Stop 9702, Rockville, MD 20850-9702.
FOR FURTHER INFORMATION CONTACT: Information on licensing and co-
development research collaborations, and copies of the U.S. patent
applications listed below may be obtained by contacting: Attn.
Invention Development and Marketing Unit, Technology Transfer Center,
National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702,
Rockville, MD, 20850-9702, Tel. 240-276-5515 or email
ncitechtransfer@mail.nih.gov. A signed Confidential Disclosure
Agreement may be required to receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Title of invention: Synthetic Human-Derived Peptides and
Peptidomimetics for Cancer Therapeutics
Keywords: Rpn13, selective proteasome inhibitor, proteasome
ubiquitin receptors, (competition: carfilzomib and bortezomib too
toxic, resistance developed), solid tumors, hematological cancer, HPV
associated cancer, ovarian cancer, prostate cancer, gastric cancer,
breast cancer, or colorectal cancer
Description of Technology: FDA approved 26S proteasome inhibitors,
such as carfilzomib and bortezomib (Velcade[supreg]) have proven to be
effective at treating hematologic cancers. However, resistance to these
agents as well as their toxicity have raised concerns and highlight the
need for new 26S proteasome inhibitors.
Investigators at the NCI's Structural Biophysics Laboratory have
developed a new class of proteasome inhibitors. They are hRpn2-derived
peptides capable of specifically targeting the Pru domain of hRpn13.
Disruption of the Rpn2/Rpn13 interaction inhibits proteolysis by a
mechanism that differs from those of the approved proteasome
inhibitors.
Potential Commercial Applications:
New class of proteasome inhibitors, targeting hRpn13 of
the regulatory particle.
Value Proposition:
Synergistic with, and more specific than, known proteasome
inhibitors.
Alternate mechanism of action compared to approved
proteasome inhibitors.
Development Stage: Discovery (Lead ID).
Inventor(s): Kylie J. Walters (NCI), Fen Liu (NCI), and Xiuxiu Lu
(NCI).
Intellectual Property:
HHS Reference No. E-278-2015/0-US-01.
US Provisional Application 62/222,530 (HHS Reference No. E-278-
2015) filed September 23, 2015 entitled ``Human RPN2 Derived Peptides
Useful For Treating Cancer''.
Publications: 1. Lu X., et al., 2015 PLoS One 2015 Oct 14;10(10)
PMID: 26466095.
Contact Information: Requests for copies of the patent application
or inquiries about licensing, research collaborations, and co-
development opportunities should be sent to John D. Hewes, Ph.D.,
email: john.hewes@nih.gov.
Dated: July 26, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology Transfer Center, National
Cancer Institute.
[FR Doc. 2016-18689 Filed 8-5-16; 8:45 am]
BILLING CODE 4140-01-P